Clinical Trials Search
Clinical Trial 18289
Cancer Type: Malignant Hematology
Interventions:Axicabtagene Ciloleucel (KTE-C19); KTE-C19
Study Type: Treatment
Phase of Study: Phase II
- Frederick Locke
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
The purpose of this study is to determine if the experimental product, KTE‐C19, when administered after participants receive a 3 day course of chemotherapy, is safe and effective in treating their Mantle Cell Lymphoma (MCL).
The Primary Objective is to evaluate the efficacy of KTE-C19, as measured by objective response rate, in subjects with r/r MCL. Secondary Objectives will include assessing the safety and tolerability of KTE-C19 and additional efficacy endpoints.